CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Pegylated Interferon-α2bWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1266 Honey Wiki 1.00
drug1865 Nigella Sativa / Black Cumin Wiki 0.71
drug2176 Placebos Wiki 0.24
drug2698 Standard of Care Wiki 0.18

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - α2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19)

This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Initial 1 mcg/kg of Pegylated Interferon-α2b will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered with recommended standard care during the trial.

NCT04480138 Covid19 Drug: Pegylated Interferon-α2b Other: Standard of Care

Primary Outcomes

Description: Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities. Hospitalized, not requiring supplemental oxygen. Hospitalized, requiring supplemental oxygen. Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Death.

Measure: Change in Clinical status of subject on a 7-point ordinal scale

Time: Week 2

Secondary Outcomes

Description: PCR for SARS-CoV-2 in pharyngeal swab

Measure: PCR test

Time: Week 2 and Week 4

Description: Occurrence of supplemental Oxygen

Measure: Supplemental Oxygen

Time: Week 2 and Week 4

Description: Occurrence of Mechanical Ventilation

Measure: Mechanical Ventilation

Time: Week 2 and Week 4

Description: Occurence of Adverse events

Measure: Incidence of Treatment-Emergent Adverse Events

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: C-reactive protein (CRP)

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: Interleukin 6 (IL-6)

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: D-dimer

Time: Week 2 and Week 4

Description: type II class of interferons

Measure: Interferon gamma

Time: Week 2 and Week 4

Description: proteins

Measure: Ferritin

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: TNF alpha

Time: Week 2 and Week 4

Description: Inflammatory Biomarker

Measure: Interleukin 1-β

Time: Week 2 and Week 4

No related HPO nodes (Using clinical trials)